Published in Cancer Weekly, March 19th, 2002
The patent relates to methods and compositions that combine the potency of DNA damaging agents, such as chemotherapy, with the delivery of a tumor suppressor gene. This patent is one of numerous patents, pending or issued, that Introgen has licensed exclusively from The University of Texas System based on technology from the University of Texas M. D. Anderson Cancer Center.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.